Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection. by Corthésy, B. & Bioley, G.
March 2018 | Volume 9 | Article 4311
Review
published: 07 March 2018
doi: 10.3389/fimmu.2018.00431
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Rajko Reljic, 









Gilles Bioley  
gilles.bioley@chuv.ch
Specialty section: 
This article was submitted to 
Vaccines and Molecular 
Therapeutics, 






Corthésy B and Bioley G (2018) 
Lipid-Based Particles: Versatile 
Delivery Systems for Mucosal 
Vaccination against Infection. 
Front. Immunol. 9:431. 
doi: 10.3389/fimmu.2018.00431
Lipid-Based Particles: versatile 
Delivery Systems for Mucosal 
vaccination against infection
Blaise Corthésy and Gilles Bioley*
R&D Laboratory, Division of Immunology and Allergy, Centre des Laboratoires d’Epalinges, Centre Hospitalier Universitaire 
Vaudois (CHUV), Lausanne, Switzerland
Vaccination is the process of administering immunogenic formulations in order to induce 
or harness antigen (Ag)-specific antibody and T cell responses in order to protect against 
infections. Important successes have been obtained in protecting individuals against 
many deleterious pathological situations after parenteral vaccination. However, one of 
the major limitations of the current vaccination strategies is the administration route 
that may not be optimal for the induction of immunity at the site of pathogen entry, 
i.e., mucosal surfaces. It is now well documented that immune responses along the 
genital, respiratory, or gastrointestinal tracts have to be elicited locally to ensure efficient 
trafficking of effector and memory B and T cells to mucosal tissues. Moreover, needle-free 
mucosal delivery of vaccines is advantageous in terms of safety, compliance, and ease 
of administration. However, the quest for mucosal vaccines is challenging due to (1) the 
fact that Ag sampling has to be performed across the epithelium through a relatively 
limited number of portals of entry; (2) the deleterious acidic and proteolytic environment 
of the mucosae that affect the stability, integrity, and retention time of the applied Ags; 
and (3) the tolerogenic environment of mucosae, which requires the addition of adjuvants 
to elicit efficient effector immune responses. Until now, only few mucosally applicable 
vaccine formulations have been developed and successfully tested. In animal models 
and clinical trials, the use of lipidic structures such as liposomes, virosomes, immune 
stimulating complexes, gas-filled microbubbles and emulsions has proven efficient for 
the mucosal delivery of associated Ags and the induction of local and systemic immune 
reponses. Such particles are suitable for mucosal delivery because they protect the 
associated payload from degradation and deliver concentrated amounts of Ags via 
specialized sampling cells (microfold cells) within the mucosal epithelium to underlying 
antigen-presenting cells. The review aims at summarizing recent development in the field 
of mucosal vaccination using lipid-based particles. The modularity ensured by tailoring 
the lipidic design and content of particles, and their known safety as already established 
in humans, make the continuing appraisal of these vaccine candidates a promising 
development in the field of targeted mucosal vaccination.
Keywords: mucosal, vaccination, lipidic particles, delivery system, infections
iNTRODUCTiON
Vaccination is considered as one of the most successful medical actions and has greatly con-
tributed to the improvement of world health. Indeed, it has strikingly reduced the prevalence 
of many infectious diseases, and thus helps nowadays to save millions of lives each year 
(1, 2). Vaccine administration aims at inducing and harnessing protective effector and memory 
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immunity, comprising neutralizing antibodies (Abs) together 
with cytotoxic and helper T cells (3) able to control subsequent 
challenge by the target pathogen. Live-attenuated or killed 
whole-pathogens have originally been administered for vaccina-
tion purposes, but due to safety concerns, including important 
reactogenicity and risks of reversion, the use of subunit vac-
cines is preferred. The latter are composed of recombinant or 
purified pathogen-derived antigenic entities, mostly depleted 
of innate immune stimulus, that require the co-administration 
of adjuvants and/or the use of delivery vehicles to achieve 
sufficient immunogenicity. Over the last decades, important 
pieces of work in the field of vaccine technology have allowed 
to rationally design and develop formulations that ensure 
efficient induction of immune responses (4). Synthetic micro-/
nanoparticles, liposomes, immune stimulating complexes 
(ISCOMs), virosomes, virus-like particles, as well as emulsions, 
all offer several interesting attributes for vaccine delivery and 
have already proven efficient in parenteral (intramuscular or 
subcutaneous) vaccinations by inducing protection against 
infectious agents (5). These formulations have been designed to 
mimic biophysical and biochemical features of pathogens, thus 
ensuring efficient display and delivery of concentrated amounts 
of antigens (Ags) and adjuvants to innate and adaptive immune 
cells. Interestingly, this leads to reducing the number of injec-
tions required to elicit potent cellular and humoral immune 
responses with minimal cytotoxicity.
Despite important success in protecting individuals against 
many deleterious pathological situations, it remains that most 
of the licensed subunit vaccines are administered parenter-
ally. However, except in previously infected individuals, such 
a route of administration only induces limited protective 
effect at the level of mucosal surfaces, the sites where the vast 
majority of pathogenic agents gain access to the host body (6). 
In addition to mechanical (epithelium covered with mucus) 
and chemical (anti-microbial peptides) barriers found at 
mucosae, adaptive humoral and cellular immunity is of prime 
importance to efficiently protect against pathogenic insults (7). 
Thus, to reinforce the efficiency of vaccination, the delivery 
of vaccine formulations directly to the mucosa represents an 
asset. It is now well accepted that immune responses have to 
be elicited locally to ensure efficient imprinting of effector 
and memory B and T  cell homing to mucosal tissues where 
they will limit entry, colonization, and spreading of pathogens 
(8–11). Until now, the few licensed mucosal vaccines consist 
in administration of live-attenuated or killed whole-pathogens 
that raise similar safety concerns as for parenteral injection, 
while no subunit vaccines have been approved for human 
use. This is mainly due to technical difficulties inherent to the 
administration route and the physiology of the tissues where 
the vaccine formulations are applied. Identifying the most 
adequate vaccine formulation deliverable mucosally remains 
challenging due to (1) the fact that, in contrast to parenteral 
vaccination where injected Ags and adjuvants are directly in 
contact with antigen-presenting cells (APCs), Ag sampling 
has to be performed across the mucus and the epithelium 
first; (2) the deleterious acidic, proteolytic, and dynamic envi-
ronment of the mucosal surfaces which impact the stability, 
integrity, and retention time of the applied Ags; and (3) the 
tolerogenic nature of the mucosa, which impairs induction 
of effector immunity to antigenic entities lacking sufficient 
immunostimulatory signals (12). Such hurdles may, however, 
be partially overcome thanks to recent progress made in the 
understanding of mucosal immunity and in the field of vaccine 
technology (6).
Apart from immunological and physiological aspects, one 
important point to be considered for vaccination is the compli-
ance of the patients (13). For pediatric vaccination, adminis-
tration has to be minimally invasive and easy to perform. The 
ability of vaccinating a large number of people in countries 
where endemic infections are present, but where access to medi-
cal infrastructures is limited, is of great importance as well. In 
this context, parenteral vaccination is not the most appropriate 
strategy as injections are invasive, painful and require trained/
skilled medical staff for administration. Moreover, it poses 
problems related to the risks associated with infection at the 
site of injection, needle-stick injury, spreading of transmis-
sible diseases, and disposal of used materials. Thus, there is an 
increasing demand for needle-free vaccination. As an example, 
mucosal vaccines display several advantages, such as ease of 
administration and self-delivery allowing mass vaccination, 
absence of needle-associated risks, and in some cases lower 
costs and simplified production due to absence of administra-
tion devices.
Until now, only few mucosally applicable subunit vaccine 
formulations have been developed and successfully tested 
(14), mainly because of the limited number of safe and effi-
cient delivery systems and adjuvants available, coupled to the 
sometimes important amounts of Ag to be administered. This 
review will focus on lipid-based micro-/nanoparticles that 
possess several of the desired characteristics of an interesting 
Ag-delivery system for vaccination as they are biocompatible, 
can overcome physiological barriers at mucosae, promote Ag 
crossing of the epithelium and uptake by APCs, protect the 
associated payload, are adequate for incorporating adjuvants 
and may display mucoadhesive properties. In order to achieve 
the induction of protective anti-pathogen humoral and cellular 
responses at the relevant mucosal surfaces, the choice of the 
most potent administration route has to be carefully consid-
ered by taking into account the physiological and immunologi-
cal features of the different target tissues (15). These aspects 
and the strategies to specifically target vaccines to the portals 
of entry across the epithelium and increase the efficiency of 
delivery will first be discussed. However, directing vaccines 
to the appropriate location is not sufficient to ensure optimal 
vaccination effect. The architecture, size, and surface chemistry 
of particles are of prime importance and can be manipulated 
to influence the intensity and type of immune responses. 
Physicochemical properties of lipid-based particles, Ag incor-
poration, mucoadhesion, and association with adjuvants will 
be discussed next. Examples of mucosal application of such 
formulations in animal models and their outcome will then 
be presented. Finally, an overview of the current evaluation of 
lipid particles and open challenges of mucosal vaccination in 
humans will be considered.
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vACCiNe SAMPLiNG AT MUCOSAL 
SURFACeS AND THe SeLeCTiON  
OF THe ROUTe OF ADMiNiSTRATiON
When applying a vaccine formulation via any delivery route, 
the anatomical, functional, and immunological characteristics 
of the different tissues have to be considered (13). Indeed, the 
structure and spatial organization of the tissues, the presence of 
mucus and mechanisms to eliminate deposited materials/particles 
(e.g., peristaltism in the intestine and physical discharge in the 
respiratory tract), the pro-tolerogenic environment of mucosae 
and the presence and localization of particular immune cell sub-
sets, especially dendritic cells (DCs), all impact on the outcome of 
vaccine administration (16). In addition, safety issues have to be 
considered. In this section, we will present the characteristics of 
the mucosal immune system in relationship with vaccination, the 
different mucosal administration routes, as well as the strategies 
under evaluation to increase the efficiency of vaccine delivery.
The Mucosal immune System and 
Mucosal vaccination
Mucosal surfaces are continuously exposed to, and challenged 
by, numerous environmental Ags present, for example, in food, 
air, or derived from pathogenic or commensal microorganisms 
in the lumen. On top of the epithelial barrier covered by mucus 
and the secretion of anti-microbial peptides, a specialized and 
complex immune network, called mucosa-associated lymphoid 
tissues, is involved in immunosurveillance of mucosal tissues 
(17). Lymphoid cells and effector molecules, such as secretory IgA 
(SIgA), the chief Ab molecule operating at mucosal surfaces (18), 
cytokines, and chemokines, tightly orchestrate protection against 
infections and maintenance of tolerance toward endogenous 
unharmful microorganisms. Sampling for such agents and their 
delivery to immune cells underneath the epithelial layer takes 
place via direct uptake by DCs within the epithelium (19–21) or 
across specialized epithelial cells named microfold (M) cells that 
are responsible for the selective transport of macromolecules, 
particulate Ags, and microorganisms (22, 23). Internalization via 
M cells occurs through different mechanisms (clathrin-coated 
endocytosis, actin-dependent phagocytosis, or macropinocyto-
sis) depending on the nature of the Ags. M cells are present in 
(a) the follicle-associated epithelium that separates the intestinal 
lumen (apical side) from underlying immune cells (basolateral 
side) in Peyer’s patches (PPs), (b) in intestinal isolated lymphoid 
follicles, (c) in nasopharynx-associated lymphoid tissues (NALT), 
and (d) in bronchial-associated lymphoid tissues (BALT) (24). 
Such structures are composed of innate and adaptive immune 
cells, including functionally different DC subsets, T, and B cells. 
DCs integrate signals derived from the sensing of the luminal 
environment, and release soluble factors, such as cytokines and 
chemokines, to orchestrate the generation of tightly controlled 
mucosal immunity locally or after migration in regional lymph 
nodes (LNs) (7). In addition, paracellular and transcellular uptake 
of macromolecules and small particles across the epithelia lead to 
their uptake by APCs outside inductive sites for induction of local 
immunity via regional LNs. By contrast, in the urogenital tract 
and in the oral cavity, the stratified epithelium does not contain 
M cells and sampling occurs by DCs interspersed within the 
tissue leading to induction of immune responses exclusively in 
draining LNs (15, 25, 26).
Upon encounter with microorganisms or vaccine formula-
tions, mucosal DCs in combination with neighboring epithelial 
cells control the expression of specific homing receptors on 
primed lymphoid cells and modulate the type of ensuing immune 
response (8, 9, 27). Such imprinting relies on the expression of 
site-specific integrins and chemokine receptors by B and T cells 
and allows their transit via the lymph and through the blood to 
migrate to different mucosal sites. Recirculation of lymphocytes 
to the gut requires expression of α4β7 and CCR9, whereas 
migration to the airways, the oral cavity, and the reproductive 
tract relies on L-selectin and CCR10. In the case of pathogenic 
infections, danger signals generated by the sensing of microor-
ganisms switch immune responses toward an effector type of 
response relying on both humoral and cellular arms to eliminate 
the infection (28). Immune exclusion and neutralization by SIgA, 
as well as production of Th1- or Th17-type cytokines that activate 
phagocytes and induction of cytotoxic T cells, all contribute to the 
protection of mucosal surfaces (29, 30). Therefore, the major aim 
of vaccines would be to elicit specific B and T cell responses at the 
relevant sites to induce specific SIgA that provide a first line of 
protection against invading pathogens, together with appropriate 
cellular immune responses to eliminate both the pathogen and 
pathogen-infected cells. For example, requirements for proper 
B  cell isotype-switching and the generation of IgA responses 
include mainly the production of TGF-β, IL-6, retinoic acid, and 
IL-21 by PPs’ cells, together with the CD40–CD40L interaction 
between T follicular helper cells and B cells (31). Thus, vaccine 
formulations for mucosal application have to be designed to best 
induce such immunological environment.
Administration Routes for Mucosal 
vaccination
Each route of mucosal administration has its own characteristics 
and a balance between the pros and cons for each vaccine has to 
be considered, taking into account the pathogen to fight against 
and the formulation to be delivered. However, no standardized 
studies are available to directly compare safety, profile of induced 
immune responses, and efficiency of protection. In this section, 
we will consider the different mucosal administration routes. Oral 
and nasal/pulmonary are the most studied ones, but sublingual 
is now recognized as a promising way of vaccination. Vaginal 
and rectal delivery have also been studied, but more scarcely. 
Even though the most powerful response is usually elicited in 
the local inductive and adjacent tissues, the common mucosal 
immune system predicts that homing to distant mucosal tissues 
is possible (27). However, a certain degree of compartimentaliza-
tion does not allow imprinted cells to migrate to every mucosal 
sites. Such flexibility allows to select for the most appropriate 
route of vaccination to induce protective immune responses at 
the desired site. Of note, some recent works demonstrated that 
transcutaneous immunizations have the potency to promote the 
induction of immune responses with the ability to traffic to the 
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gut and airways, although up to now with low consistency (32). 
However, this aspect will not be covered by this review and has 
been described elsewhere (33, 34).
Nasal administration represents a promising route for mucosal 
vaccination (35), because nasal tissues display a relatively large 
surface for Ag absorption covered with only a thin layer of mucus, 
and are highly vascularized. It does not require the delivery of 
high Ag doses (e.g., as compared to oral administration), is 
non-invasive and easily accessible for self-administration. Nasal 
vaccination allows the generation of a broad range of Ab and 
T  cell responses at different mucosal sites, such as the upper 
(preferentially) and lower airway mucosae, the local secretions, 
the salivary glands, and the urogenital tract. It also elicits con-
comitant robust systemic immunity (15). However, in the nasal 
environment, the presence of proteases and the local pH, together 
with a relatively high mucoscillary clearance rate, may impact 
on the vaccine integrity and retention time, thus affecting the 
generation of immune responses. The major drawback concerns 
the safety of nasal administration, as physiological function such 
as smell perception might be altered by vaccine-induced inflam-
mation and the close relationship with the brain might promote 
health problems. Thus, every vaccine candidate has to be evalu-
ated carefully for safety. Sometimes achieved by nasal delivery 
or directly targeted, pulmonary immunization allows vaccine 
formulation to directly access the respiratory tract which is of 
interest due to its high permeability, its large surface area and the 
high density of APCs (alveolar macrophages, DCs, and B cells). 
This route of administration preferentially induces immune 
responses in the lower airways and has interestingly been shown 
to promote cellular and humoral responses in the gut. However, 
efficient delivery in the lung is not an easy task. Delivery via the 
nasal and pulmonary routes does not necessarily lead to similar 
outcomes: for example, pulmonary vaccination was shown to be 
more effective than its nasal counterpart at protecting against 
Mycobacterium tuberculosis infection, because different immune 
mechanisms were involved after one or the other administration 
route (36–38). Indeed, elevated levels of SIgA were produced in 
the lung after pulmonary vaccination, with equivalent responses 
observed in the nasal passage. In addition, IFN-γ production in 
the lung following pulmonary vaccination was important to fight 
against M. tuberculosis, whereas there was apparently no role for 
this cytokine in the nasal environment.
Oral administration represents an interesting strategy in terms 
of ease of delivery, patient compliance, and safety (39). However, 
due to the intrinsic high dilution of vaccine formulations and the 
harsh environment of the digestive tract, substantial amounts of 
Ags have to be administered. Indeed, the extremely low pH in the 
stomach, proteolytic enzymes and bile salts in the intestine, the 
presence of relatively thick one-layered mucus, and the overall 
low permeability of the intestine greatly affect the integrity and 
delivery of applied Ags. In this context, oral vaccines are likely 
to be more efficient if repeated doses are given, provided that 
adjuvants are incorporated to avoid tolerance induction (13). 
Oral administration is the most efficient delivery route to achieve 
induction of gut immunity, which is of high importance to fight 
against the large burden of enteropathogenic infections world-
wide. Induction of immune responses in the colon, stomach, 
mammary, and salivary glands, as well as systemically, also takes 
place, but with limited robustness (15).
Sublingual immunization generates immune responses with 
similar profile and mucosal tropism as nasal delivery, i.e., vigor-
ous and broadly disseminating mucosal and systemic IgA and 
IgG, as well as helper and cytotoxic T cell, responses (40), without 
many side effects (41), and formulation concerns associated 
with nasal or oral immunization (42). It is also easily accessible 
for self-administration. It has been shown to induce immune 
responses after administration of soluble Ags, particulate Ags, 
live/killed bacteria, and viruses (40). Sublingual delivery is 
interesting because the oral cavity has a milder environment that 
may not degrade vaccine components, and may, thus, not require 
large amounts of Ags. As an example, higher Ab responses were 
obtained in mice after sublingual, as compared to oral, adminis-
tration with about 10–50 times less Ag applied (43). One limiting 
factor is the absence of Ag-sampling M cells in the oral cavity 
lined by a stratified epithelium and the relatively low number of 
DCs in the upper layer of oral tissues. However, vaccine formula-
tions can be taken up by lingual tonsils for delivery into regional 
LNs and Langerhans cells in the oral epithelium have been shown 
to act as potent inducers of immunity (15). Several delivery sys-
tems (microneedles, liposomes, inactivated microorganisms) and 
adjuvants [toll-like receptor (TLR) ligands, cholera toxin (CT), 
mutants of heat labile toxin (LT) and CT] have been evaluated for 
sublingual vaccination and protective Th1-type responses in the 
lung, genital tract, and the gut, together with SIgA in the saliva, 
intestinal, and vaginal washes, have been obtained with different 
vaccine formulations (42–45).
Vaginal immunization elicits immune responses in the genital 
tissues and secretions, but is not efficient to induce systemic 
immunity. Despite relatively low pH, the vagina is a mild environ-
ment that does not impair Ag integrity and, thus, allows to limit 
the amount of Ag to be delivered (25). However, the presence of 
a stratified epithelium and the absence of inductive sites imply 
that induction of vaccine response via vaginal delivery requires 
specific adjuvanted formulations and DC subsets (46). In addi-
tion, the changes occurring in term of immunological functions 
during the estrous cycle complicate such immunization (47–49). 
Additional studies are required to better understand mucosal 
immunity in the urogenital tract and define specific requirements 
for vaccine formulations. Rectal immunization is able to induce 
potent immune responses in the small intestine and the colon, but 
not efficiently in the systemic compartment (15). Only limited 
studies are available to fully appreciate the potential of such an 
administration route for mucosal vaccination.
Targeted Delivery of vaccine Ags
Not only do vaccine formulations have to resist the deleterious 
environment of some mucosal surfaces, but they also have to face 
an additional hurdle that is to cross the epithelium to gain access to 
underlying APCs. In this context, targeting the relatively low num-
ber of portals of entry at inducing sites, e.g., M cells that represent 
1% of epithelial cells (5–10% of enterocytes within the follicular- 
associated epithelium), or DCs spread within the epithelium is 
an asset for efficient vaccination. DC targeting by the mean of 
C-type lectin receptors (DEC205, DC-SIGN, mannose receptor) 
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or specific Abs directed against DC markers has proven to be an 
efficient strategy to improve the potency of parenteral vaccination 
(50). Similar strategies have been developed for mucosal vaccina-
tion, such as targeting of Langerin on DCs of the oral cavity, the 
esophagus or the vaginal mucosa (51). FcRn expressed by airway 
and gut epithelial cells (52, 53), as well as some DC subsets (54), 
has also been demonstrated as an efficient strategy to deliver IgG-
based complexes across the epithelium and to underlying DCs. 
Such an approach efficiently led to the induction of both CD4 
and CD8 T cell effector responses (55–57). Galactosyl ceramide 
may function as a targeting moiety in the intestine, the rectum, 
and the endocervical mucosa (58), and the ganglioside GM1 
molecule can be targeted by a specific peptide developed by phage 
display (59). As far as M cells are concerned, specific delivery can 
be achieved via different strategies: the tight junction molecule 
claudin-4 (60), the bacterial FimH receptor GlycoProtein-2 
(61, 62), the complement C5a receptor and its ligand Co1 (63, 64), 
a M-cell-specific peptide referred to as CKS9 (65), or the unique 
glycosylation pattern involving α-1-fucose; for the later, the use 
of Ulex Europaeus Lectin-1, or a specific monoclonal Ab have 
been successfully demonstrated (66–68). However, in humans, 
the lack of expression of this particular sugar moiety on M cells 
(69), together with the extra-M cell expression of GP-2 (70), pre-
cludes the use of such strategies for specific targeting purposes. 
By contrast, a promising approach consists in coupling vaccine 
Ags with SIgA in order to induce M-cell-specific retrotransport 
across the epithelium and DC targeting via Dectin-1 in both mice 
and humans (71). This Ab molecule can potentially serve as a 
cargo for the controlled delivery of the associated payload as this 
occurs naturally with microorganisms sampled from the mucosal 
lumen (72). An additional advantage is the resistance of SIgA to 
protease degradation and its ability to anchor in mucus (18), two 
features that may improve both stability and retention time of the 
associated Ags.
FORMULATiON CONSiDeRATiONS
Particulated Ags have been designed to mimic the shape, size, and 
antigenic display of pathogens with the aim of improving vaccine 
efficiency (73). Ags associated with micro-/nanoparticles display 
increased depot effect upon administration, are better protected 
from degradation, and are more efficiently taken up by APCs and 
presented to B and T cells than soluble Ags (74). An important 
number of studies have evaluated the effect of particle properties 
(type of material, size and charge, Ag incorporation, or associa-
tion of adjuvants) on the profile and strength of induced Ab and 
T cell responses. When composed of natural lipids, lipid-based 
particles have the advantage of being biocompatible. In addition, 
they are very flexible in terms of formulation, implying that lipid 
exchange within the particle shell is achievable, leading to modu-
lation of their physico-chemical properties. This is of importance 
in the biological environment because all these parameters 
will influence the stability and immunological consequence of 
delivered particles. However, minor changes in the composition 
of the particle may impact on its efficiency and protective ability, 
meaning that any formulation needs to be individually evaluated 
in vivo.
Size and Charge of Particles
The size of particulate Ags has an impact on the type of immune 
responses that are generated because it influences the mechanism 
of uptake by APCs. Indeed, receptor-mediated endocytosis, 
pinocytosis, macropinocytosis, or phagocytosis, all lead to dif-
ferent ways of trafficking within the cells and, therefore, induce 
preferentially presentation via the MHC I or MHC II pathway 
for CD8 or CD4 T cell priming, respectively (75). Small parti-
cles (up to 200  nm) are sensed as viruses and are taken up by 
receptor-mediated endocytosis leading to predominant T  cell 
responses, whereas larger particles (more than 500 nm) are taken 
up via micropinocytosis or phagocytosis to preferentially induce 
Ab responses (76). Similar size-dependent uptake by M cells 
or enterocytes takes place, leading to differential sampling of 
the particulated Ags. Other studies demonstrated that vesicles 
smaller than 250  nm induced a balance toward Th2-type of 
responses, whereas the opposite was observed for larger vesicles 
(77–79). Moreover, in the context of mucosal delivery, the size of 
the particles influences the tissue localization and the diffusion 
across the mucus. Following nasal administration, small particles 
are better transported across the nasal mucosa, whereas larger 
ones are better deposited in the respiratory tract to be taken up 
by alveolar macrophages (80, 81). In order to get access to the 
epithelium, both viscosity and pore size of mucus can impact on 
the penetration of vaccine components. Apparently, the average 
size of pores in the mucus is in between 200 and 500 nm, e.g., in 
the cervicovaginal and small intestinal mucus. This suggests that 
particles smaller than this cutoff freely diffuse across the mucus, 
whereas larger ones take more time to reach the epithelium or 
possibly never reach it (82, 83). One major point to be considered 
is that correlation between size and immunogenicity is difficult to 
strictly assess for lipid-based particles, because homogeneous and 
monodispersed preparations have been challenging to obtain, 
and when feasible, such preparations require technical issues that 
may dramatically increase the cost of vaccine formulations.
Diffusion across the mucus is not only governed by size of 
particulated Ags or mucus pores but also by chemical charac-
teristics such as the surface charge of particles. Hydrophobic 
and electrostatic interactions mediated by particles aggregate 
mucus microstructure and impede diffusion of vaccines, while 
hydrophilic and neutral vaccine formulations promote mucus 
penetration (23). Mucoadhesion is promoted by positively 
charged particles that interact with negatively charged mucus. 
For example, electrostatic interactions between cationic lipids 
and the nasal mucosa promote enhanced contact time with the 
tissue, higher local concentration, and thus improved penetration 
of liposomes (84). Similarly, cationic particles better interact with 
negatively charged cell membranes, such as those of M cells and 
enterocytes, therefore limiting vaccine clearance and improving 
sampling via endocytosis or membrane fusion (85, 86); it also 
improves the uptake by DCs (87). However, cationic particles 
may have charge-dependent cytotoxicity against target cells; 
therefore, the density of cationic lipids within the particle shell 
has to be carefully defined and a tight balance between strong 
adhesion and safety has to be achieved (23). Interestingly, it seems 
that the presence of the mucus limits cytotoxicity (85), meaning 
that cationic particles keep their validity for mucosal vaccination.
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incorporation of Ag
There are different ways of associating Ags to lipid-based delivery 
systems and the choice depends mainly on the administration 
route and the nature of the Ags (88, 89). For oral administra-
tion, encapsulation seems favorable in terms of ensuing immune 
responses, because it prevents rapid degradation of the Ag within 
the gastrointestinal environment and, hence, increases its half-life 
(90). Encapsulation of Ags is relatively easy to perform during the 
manufacture process, but this may alter antigenic structures. By 
contrast, maintenance of the integrity of the Ags is less affected 
by the nasal route, suggesting that surface association via charge 
interaction is sufficient. Such an approach is technically not 
demanding, owing that opposite charges of either the particles 
or the Ags favors it (90). Alternatively, covalent binding at the 
surface of particles is achievable, although more complicated to 
perform; this precludes the undesired release of the payload that 
may occur within the tissue environment. In terms of immune 
response induction, encapsulation within liposomes preferen-
tially induces IgG production, whereas surface display of the Ag 
induces both IgM and IgG responses (91), with elevated levels 
(92). In addition, Ag density at the surface of particles, as well 
as the Ag-to-lipid ratio, has been documented to influence the 
elicited immune responses following immunization (93, 94). This 
may suggest that both encapsulation and surface location of the 
Ag within the same formulation would promote optimal induc-
tion of T cell and B cell responses.
Apart from protein Ags, plasmid DNA coding for pathogen-
derived Ags have been evaluated for vaccination (95, 96). Such 
strategy has an established record of efficacy in preclinical studies 
and can be safely used in humans, even in immunocompromised 
individuals. However, based on results obtained in the field of 
veterinary vaccination, naked DNA induces only weak immune 
responses. In order to improve immunogenicity, association of 
DNA with cationic liposomes leads to increased uptake by target 
cells and delivery into the nucleus. DNA immunization through 
the nasal or the oral route can effectively induce protective humoral 
and cellular immunity at related mucosal surfaces, but neces-
sitates association with cationic delivery systems, presumably 
to increase mucus penetration, to reduce mucociliary clearance, 
and to improve permeation across the epithelium (97, 98). DNA 
sequences such as the canonical CpG motifs have been shown 
to display immunostimulatory properties. In a similar way, mes-
senger RNA-based vaccines, when approprietely protected from 
ribonucleases are translated in the cytoplasm and do not require 
nuclear transport (99). This has been mainly evaluated with cati-
onic lipid-based vesicles in the context of cancer immunotherapy, 
and the efficient nasal application of particle-associated mRNA 
has been demonstrated (100).
Mucoadhesive Properties
Upon mucosal administration, vaccine formulations are diluted 
in mucosal fluids and have to face bulk flow, leading to limited 
retention time and suboptimal access to the epithelium for 
sampling. Such deleterious effects can be compensated by incor-
poration of mucoadhesive and mucus-penetrating components. 
In this case, the surface structure of lipid-based particles has to 
be carefully designed to obtain an adequate balance between 
strong adhesion and mucus penetration. Some possible strate-
gies are described below. The first one consists in incorporating 
polyethylene glycol (PEG) at the surface of particles. PEG has 
originally been used for systemic administration in order to avoid 
adsorption of plasma proteins and the formation of a corona that 
may mask targeting ligands, adjuvants, or Ags at the surface 
of particles (101). In addition, the presence of PEG increases 
the stability upon administration. A similar stabilization effect 
has been reported in the case of oral or sublingual delivery of 
liposomes (93, 102, 103). PEG is a hydrophilic component that 
has been reported to help particles to penetrate the nasal mucosa 
by preventing aggregation and thus facilitating diffusion across 
the mucosal barrier. Moreover, it can form hydrogen bonds with 
mucus leading to mucoadhesion, but also helps diffusion across 
the mucus; indeed, such intriguing bifunctionality has been cor-
related with the molecular weight of PEG. High molecular weight 
polymers (>PEG5000) are preferentially mucoadhesive whereas 
lower ones (PEG2000) better diffuse within the mucus (103–105). 
An additional non-negligible advantage of PEG is that it provides 
cryopreservative functions during particle manufacture.
The second strategy is to associate with micro-/nanoparticles 
some mucoadhesive components, such as chitosan (deacetylated 
chitin), alginate, polyvinyl alcohol, hyaluronan, or cellulose 
derivatives that all boost particle-based vaccination (106–108). 
Addition of bioadhesive components (xanthan gum or tramella) 
within formulations helps to increase the viscosity of the vaccine 
and, thus, the retention time at mucosal surfaces. The most studied 
mucoadhesive molecule is chitosan, whose relevant properties for 
mucosal vaccination are as follows: (1) it is a positively charged 
molecule that can interact with negatively charged mucus to 
improve adhesion; (2) it is a permeation enhancer due to its 
ability to transiently open epithelial tight junctions and, thus, 
improve Ag sampling (109); and (3) it has adjuvant properties, 
promoting induction of IFN-γ, IgG, and SIgA (110). Chitosan 
has been explored for delivery via oral, nasal, and pulmonary 
routes in association with liposomes leading to increased stabil-
ity and mucoadhesion for absorption by mucosal surfaces (111). 
Interestingly, it did not demonstrate detrimental effects toward 
mucosal tissues (112).
incorporation of Adjuvants
Several adjuvants have been evaluated during the last decades 
for mucosal vaccination (113). Essential properties of the ideal 
adjuvant include the following: to be effective with low-dose Ag; 
to be suitable with many different Ags; to be effective enough to 
reduce the number of vaccine administrations; to be able to induce 
long-term immune responses; and to display limited or absent 
toxicity. Innate immune triggers have been used as adjuvants as 
they have the capacity to elicit pro-inflammatory responses to 
recruit phagocytes, to enhance Ag presentation by APCs, and to 
activate APCs in order to generate the adequate environment for 
efficient priming of adaptive immunity. Studies in animals have 
demonstrated an important adjuvant effect of the Vibrio cholerae 
endotoxin CT and Escherichia coli LT, ensuring enhanced Ag 
permeation through the epithelium, enhanced targeting of 
M cells, increased Ag presentation by DCs and improved activation 
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of DCs (114); a direct effect on B and T cells has additionally been 
reported (15). However, such adjuvants are inadequate for human 
use because of their toxicity and unacceptable side effects, as for 
example: induction of deleterious inflammatory response leading 
to altered function of olfactory nerves or to Bell’s palsy after nasal 
administration, and diarrhea symptoms after oral administration 
(115, 116). This has oriented research toward the generation of less 
toxic derivatives engineered by introduction of mutations in the 
A subunit of CT and LT (117–120). The most promising deriva-
tive is the double mutant LT (R192G/L211A, dmLT) that has no 
demonstrated side effects in animal application while retaining 
important adjuvant activity after oral or sublingual administra-
tion (121–123). Similar mutations R192G/L211A applied to CT 
similarly reduced its toxicity, although to a level still not acceptable 
for human use. Introduction of additional mutations within the 
amino acid 189–197 stretch recently demonstrated more safety 
with an ability to induce both Ab and T cell responses close to 
that of the non-mutated CT following nasal, oral, and sublingual 
vaccinations (124). An alternative approach is the use of the B 
subunit of LT or CT only. LTB and CTB are not very efficient 
via the oral route, however, nasal administration demonstrated 
some efficiency when the Ag was physically linked to the adjuvant 
resulting in increased uptake across the epithelium and by DCs 
(15). Fusion protein obtained by association of the A1 subunit 
of CT and S. aureus protein A derivative (CTA1-DD) proved 
efficient at boosting B cell responses after nasal administration 
(125). In another report, edema toxin from Bacillus anthracis and 
diphtheria toxoid within lipidic particles have been evaluated for 
nasal administration and showed efficient induction of immune 
responses leading to reduced bacterial load after pathogen chal-
lenge (126).
In parallel, evaluation of immunostimulatory molecules active 
for parenteral administration, such as TLR ligands, have been 
performed (113). CpG oligodeoxynucleotides (CpG), monophos-
phoryl lipid A (MPLA), and flagellin that are ligands for TLR-9, 
TLR-4, and TLR-5, respectively, have been administered orally 
or intranasally and demonstrated immunostimulatory proper-
ties for mucosal immune responses, including induction of SIgA 
(127–131). Pulmonary delivery of a M. tuberculosis-derived Ag 
together with CpG or MPLA promoted the generation of IFN-γ 
production in the lung; MPLA was more potent to induce IL-17 
production and to decrease the bacterial load following chal-
lenge (132). Flagellin, expressed by different pathogenic bacteria, 
can indirectly stimulate local DCs following nasal delivery, and 
induce mucosal IgA responses and protection upon Influenza 
vaccine administration (133, 134). Alternatively, trehalose 
dibehenate (TDB), a synthetic analog of a M. tuberculosis cord 
factor known to interact with Mincle and promote Th1/Th17-
type of responses (135), has also been shown to be effective by 
the nasal route (136). Saponin QS21 also demonstrated potent 
adjuvant effect when nasally administered (128, 129). In addition, 
STING ligands 3′3′-cGAMP, c-di-AMP, and c-di-GMP have been 
efficiently delivered via the nasal or the sublingual route to elicit 
Th1/Th17 responses and high-affinity SIgA (137). Activation 
of NKT cells by administration of α-galactosylceramide is also 
of interest for nasal, oral, and sublingual vaccination due to its 
ability to enhance immunogenicity of different mucosal vaccine 
formulations (138–140). All these adjuvants can be incorporated 
within lipid-based particles or associated at their surface depend-
ing on the localization of their cognate receptor in target cells. 
This has been successfully achieved and resulted in improved 
uptake by and activation of DCs (141). Moreover, cationic lipids 
per se have been shown to directly activate APCs (142).
LiPiD-BASeD PARTiCLeS FOR  
MUCOSAL vACCiNATiON
In order to induce efficient and protective immune responses by 
vaccination, not only the Ags and the adjuvants have to be care-
fully defined, but also an appropriate delivery system is of prime 
importance. When aiming at using mucosal routes of administra-
tion, they must be designed to resist chemical degradation by low 
pH, proteolytic enzymes, and the harsh environment of mucosal 
surfaces. Lipid-based particles represent interesting delivery 
systems to incorporate Ags and adjuvants, allowing targeted 
and concentrated delivery of relatively low amounts in tissues, 
together with limiting toxicity associated with potential spread-
ing of the payload (Figure  1). Many lipid-based particles have 
been tested in animal models of immunization and/or infection 
and are reviewed below (Table 1). Advantages, limitations, and 
necessary refinements for use as effective mucosal vaccine are 
discussed sequentially.
Liposomes
The enormous potential of liposomes for drug delivery has been 
acknowledged for decades. Indeed, they display features includ-
ing controlled release, protection from degradation, improved 
pharmacokinetics, increased circulation time, and targeting to 
specific tissues (143, 144). They have been progressively adapted 
for administration of diverse antigenic entities, such as proteins, 
peptides, and DNA, in order to produce vaccine formulations to 
fight against several viral and bacterial infections (89). Liposomes 
are spherical vesicles consisting in unilamellar or multilamellar 
shell of phospholipid bilayer(s) entrapping an aqueous core and 
range in size from tens of nanometers to several micrometers 
in diameter. The amphiphilic nature of phospholipids mediates 
self-assembling of liposomes in an aqueous environment leading 
to a bilayer configuration. They can incorporate both hydrophilic 
molecules encapsulated within the aqueous core and hydropho-
bic molecules hooked at their surface or inserted within the inner 
hydrophobic space of the lipid bilayer. Biocompatible neutral 
and anionic phospholipids, such as phosphatidyl cholines [e.g., 
distearoylphosphatidylcholine (DSPC)], and cholesterol, are the 
most commonly used constituents of the shell that ensures proper 
stability of the structure and improved immunogenicity of the 
formulation (145, 146). The length and degree of saturation of 
acyl chains influence both the permeability and the fluidity of 
the shell, leading to increased or decreased stability. Liposomes 
are versatile delivery systems that are interesting for vaccination 
formulations because their physicochemical properties can 
be modulated by altering their composition in lipids. Among 
possible modifications, pH titrable lipids to induce controlled 
release of payloads (147, 148) and synthetic cationic lipids to 
FiGURe 1 | Schematic representation of lipid-based particles evaluated for mucosal vaccination. Liposomes can be tailored to incorporate particular lipids (cationic 
lipids, polar lipids from Archea), Influenza extracts or non-ionic surfactants in order to improve stability and immunogenicity of vesicles. Other lipid-based structure 
incorporating saponin, entrapping inert high molecular gas, or composed of emulsions has been developed for vaccination purposes. Black triangles represent Ags. 
They can be entrapped in aqueous cores, entrapped in hybrophobic parts, associated at the surface of particles through electrostatic interactions, or covalently 
linked at the surface of particles. Not drawn on scale.
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improve immunogenicity (90) have been generated. In addition, 
functionalization of liposomes with specific targeting moieties 
has emerged as a promising strategy to improve delivery. Vesicles 
bearing the DC-SIGN-specific ligand Lewis  x  glycan showed 
increased DC-targeting properties and subsequent activation 
of T  cells, especially when adjuvanted (141) and IgG-coupled 
liposomes have demonstrated enhanced transmucosal transport 
in nasal tissues (55).
Cationic liposomes prepared with dioleoyltrimethylammoni-
umpropane (DOTAP), dimethyldioctadecylammonium bromide 
(DDA), dimethylaminoethane-carbamoyl (DC)-cholesterol have 
been successfully evaluated. Nasal administration of DDA-based 
liposomes induced greater local and vaginal IgA production 
as compared to vesicles without cationic lipid. Moreover, the 
incorporation of PEG further increased the observed immune 
responses (149). Similarly, delivery of cationic liposomes com-
posed of DOTAP and DC-cholesterol via the nasal route allowed 
efficient uptake by DCs in NALT and subsequent induction 
of specific IgA and T  cells in nasal tissues (150). The adjuvant 
CAF01 is a prime example of efficient cationic liposomes to be 
used for mucosal vaccination. Incorporation of both DDA and the 
immunostimulatory molecule TDB, has been evaluated in several 
animal models of infections with Influenza, Chlamydia and 
M. tuberculosis (151). In such context, the presence of the adju-
vant had a substantial beneficial effect on immunogenicity (152). 
Nasal vaccination against Influenza or Streptococcus pyogenes 
with CAF01-based formulations allowed to generate mucosal 
effector T cell and IgA responses and to protect vaccinated ani-
mals (136, 153). Furthermore, preparation of liposomes with the 
cationic lipid ceramide carbamoylspermine efficiently stimulated 
systemic and mucosal immunity following intranasal administra-
tion (154). The use of cationic preparations is also an interesting 
approach for alternative forms of antigenic entities, as liposomes 
incorporating DOTAP and a plasmid DNA coding for a myco-
bacterial heat-shock protein given nasally induced local mucosal 
immune responses able to reduce M. tuberculosis load in the lung 
(155). Overall, liposome-based vaccination via the nasal route 
leads to the induction of robust immune responses whatever the 
nature of the Ag and its mode of incorporation. Thus, fine-tuning 
modulation of the profile of vaccine-elicited responses appears 
to depend on the composition of the formulation, including the 
type of lipids and/or the presence of adjuvants. Interestingly, most 




Liposomes Bilayer of phospholipids  
entrapping an aqueous core
Nasal, oral Flexibility in lipid composition, 
ease of Ag/adjuvant 
incorporation, immunogenicity 
of cationic liposomes
Relatively low intrinsic 
stability for storage and after 
administration
Potent toxicity of cationic 
lipids (dose-dependent)
Archaeosomes Liposomes composed of  
Archaea-derived polar lipids
Nasal, oral Improved immunogenicity Improved stability as 
compared to liposomes
Preparation of Archea lipids
Niosomes, 
bilosomes
Cholesterol-based liposomes with 
non-ionic surfactants and bile salts
Oral Ease of manufacture Improved stability as 
compared to liposomes
Low flexibility in lipid 
composition, low 
immunogenicity
Virosomes Liposomes containing lipidic  
viral extracts
Nasal, sublingual Immunogenic without addition 
of adjuvant
Good stability Purification of Influenza 
extracts
ISCOMs Cage-like structure made of 
cholesterol, phospholipids  
and Quil A saponin
Nasal, oral, 
vaginal
Self-adjuvanted due to saponin Good stability Difficult to incorporate 
non-lipidic Ags
Microbubbles Monolayer of phospholipids/palmitic 
acid entrapping an inert gas
Nasal, oral Flexibility in lipid composition Limited stability upon 
reconstitution and 
administration
Difficult to entrap Ags
Emulsions Oil-in-water nanosized droplets Nasal, oral Ease of manufacture, 
self-adjuvanted
Limited stability after 
administration
Low protection of Ag 
structure
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liposomal preparations seem to be well tolerated, inducing only 
limited inflammatory responses, irritation, sneezing, or burning 
syndroms. Oral administration of liposomes has been docu-
mented, but its stability in the gastrointestinal tract remains the 
main concern. As already discussed in Section “Mucoadhesive 
Properties,” promising approaches can be envisaged to improve 
the stability of liposomal preparations. Incorporation of man-
nose, chitosan, and PEG are all possible scenarios resulting in 
reinforced stability, better targeted delivery across the epithelium 
and to APCs, and improved immunogenicity. Stabilization of 
liposomes with layer-by-layer deposition of polyelectrolytes also 
increased the generation of Ab and T cell responses in mucosal 
tissues (156). The administration of multilamellar prepara-
tions is an alternative strategy. Finally, as discussed in Section 
“Administration Routes for Mucosal Vaccination,” vaccination 
via the sublingual route is a promising development that requires 
to be further evaluated for liposomal preparations in the context 
of infectious diseases. For example, PEG-modified liposomes 
incorporating Influenza-derived Ags, together with the TLR-4 
agonist CRX-601 as adjuvant, were effective at eliciting elevated 
levels of serum neutralizing Abs and mucosal IgA (103).
Liposome-Derivatives
Derivatives of liposomes have been explored to circumvent some 
of the drawbacks associated with liposomes and to improve their 
efficiency. For example, association of non-ionic surfactants 
with cholesterol or its derivatives to generate a structure called 
niosomes has allowed to increase the stability of the bilayer 
vesicles by preventing oxidation of the lipids (157). Addition of 
mannan at the surface of niosomes further increased the stability 
of the vesicles and helped to target specific receptors on APCs 
following oral administration. Vaccination with niosomes incor-
porating plasmid DNA coding for an Hepatitis B Ag induced SIgA 
production in the salivary and intestinal fluids, together with 
systemic Th1-type T cell responses (158). Moreover, incorpora-
tion of bile salts within niosome structures (bilosomes) has been 
shown to increase the stability of the vesicles and thus to improve 
oral delivery of peptides and proteins to the gut immune system 
(159, 160). Bile salts, such as deoxycholic acid or taurocholic 
acid, are amphiphatic molecules that can be easily incorporated 
within lipid bilayers and can promote the passage of lipophilic 
components across cell membranes (161). Thus, bilosomes have 
the ability to reinforce the biovailability of associated Ags mainly 
for oral vaccination (162). Different examples of bilosome appli-
cation have been reported in association with Hepatitis B-derived 
Ags and Tetanus toxoid. In this context, induction of SIgA in 
mucosal secretions and IgA-positive plasma cells were observed 
(162–164) and showed elevated responses as compared to paren-
teral injection or use of niosomes without bile salts. An alterna-
tive approach is the inclusion of polar lipids with fully saturated 
isoprenoid chains extracted from Archaea to generate vesicles 
called archaeosomes or archaeal lipid mucosal vaccine adjuvant 
and delivery (AMVAD) (165). They have been shown to induce 
robust long-lasting protective Ab and T cell responses, including 
cytotoxic T lymphocytes responses after systemic injection (166). 
Advantages of such structures for mucosal vaccination comprise 
increased pH-dependent and thermal stability due to prevention 
of lipid oxidation and resistance to phospholipases and bile salts. 
In this context, mice immunized by the nasal route demonstrated 
sustained robust local and distant IgA responses in mucosal 
fluids, strong systemic IgG responses, and T cell responses (167). 
In addition, nasal vaccination with archaeosomes and cell-free 
extracts of Francisella tularensis led to reduced bacterial burden 
in the lung and spleen in a mouse model of tularemia (168). Oral 
immunization with archaeosomes is possible as well, although 
with higher amounts of Ags. Improved stability and retention 
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time of such vesicles has been observed in the intestine, leading 
to potent IgG and IgA production (169). One non-negligible 
drawback of this approach is the access to achaeal polar lipids, as 
the purification from Archaea is a relatively demanding process. 
Nevertheless, production of synthetic polar lipid structures is 
under development.
virosomes
Virosomes are a special category of liposomes, where part of the 
lipid content is derived from viral components that self-assemble 
into an organized three-dimensional structure that mimics the 
antigenic structure of the original virus (170). Interestingly, they 
have been demonstrated to be immunogenic without further 
addition of adjuvants (171), although addition of immunopo-
tentiating agents further improves their vaccine efficiency (172). 
Originally called immunopotentiating reconstituted Influenza 
virosomes, they harbor hemagglutinin and neuraminidase pro-
teins from Influenza virus. These proteins target sialic acid on cell 
membranes, leading to fusion between the target cell and viro-
somes, followed by intracellular delivery of their payload. They 
exhibit similar flexibility and advantages as standard liposomes; 
however, the process to extract all the necessary components 
from Influenza virus is relatively complex. Virosomes have been 
mainly investigated for parenteral vaccination, but reports on 
their use for mucosal administration exist. They have been used as 
prime-boost vaccination strategy in a simian model of HIV infec-
tion, where intramuscular injections have been followed by nasal 
administration. It induced full protection against vaginal simian-
HIV challenge that was correlated with the presence of mucosal 
IgA and IgG with blocking activity against virus transcytosis 
and neutralizing/Ab-dependent cellular cytotoxicity properties, 
respectively (173). In mice, nasal or sublingual administrations of 
adjuvanted virosomes were able to protect against Influenza and 
respiratory syncytial virus infections by promoting mucosal and 
systemic Ab responses, together with Th1-type cellular responses 
(174–176).
Gas-Filled Microbubbles
Gas-filled microbubbles are microsized spherical structures 
composed of a lipidic, denatured protein-based, or crosslinked 
polymer shell generally entrapping inert high molecular weight 
gases to ensure resistance to pressure once administered (177). 
Due to their strong echogenicity in presence of low ultrasound 
intensities, they are currently used for human application as 
intravenously delivered echo-contrast agents to more precisely 
visualize for example angiogenesis in malignant tumors, left 
ventricular opacification, and myocardial perfusion. In addition, 
cavitation induced by higher ultrasound application leads to 
the transient nonlethal permeability of the surrounding tissue 
(e.g., vascular barriers or cell membrane) allowing enhanced local 
on-demand extravasation and bioavailabilty of microbubble-
associated payload (178). In the last decades, such a process, 
known as sonoporation, has received important attention in order 
to improve delivery of a wide range of therapeutic molecules, 
including chemotherapeutic agents, siRNA, miRNA, oligonu-
cleotides, or plasmid DNA, to tumor or immune cells (177, 179). 
Typically, sonoporation has been used for improved delivery of 
Ags into DCs with the aim of boosting immune responses (180). 
Interestingly, lipid-based microbubbles can be taken up by APCs 
and deliver intracellularly their antigenic payload without ultra-
sound application, leading to processing and presentation of the 
Ag to responsive T cells (181, 182). Furthermore, microbubble-
associated Ags can be injected parenterally as a vaccine formula-
tion to elicit potent and long-lasting immune responses against 
systemic bacterial infection (183, 184). Lipid-based microbubbles 
are usually composed of phospholipids (e.g., DSPC) and palmitic 
acid, but tailored formulations can be prepared by incorporation 
of cationic lipids in their shell in order to better associate DNA 
(179). In addition, to improve the specificity of imaging and drug 
delivery, microbubbles can be targeted to particular tissues by 
linking cell-specific ligands or Abs has been developed at their 
surface (185, 186). Such aspects are of interest for mucosal vacci-
nation using targeting strategies as discussed in Section “Targeted 
Delivery of Vaccine Ags.” Moreover, adjuvants can be associated 
with microbubbles, which results in enhanced immunogenicity 
of the vaccine preparations. As an example, nasal delivery of 
α-galactosylceramide-adjuvanted microbubbles displaying the 
Salmonella-derived SseB Ag at their surface were able to induce 
potent IgA, IgM, and IgG humoral responses in the gut, which were 
associated with a Th1-/Th17-type cellular response. This resulted 
in a significant decrease in local and systemic bacterial load fol-
lowing oral infection with Salmonella enterica Typhimurium in 
prophylactically vaccinated mice; such effect was more potent 
than parenteral injection of the same microbubble formulation 
(140). Despite so far limited induction of local immune responses 
after oral administration, improvement of microbubble formula-
tions may lead to enhanced immunogenicity. Moreover, sublin-
gual administration remains to be tested owing to its valuable 
advantages in the context of mucosal vaccination. In recent years, 
nanosized bubbles have been developed that showed increased 
stability and extravasation following systemic administration, 
suggesting that such derivatives might be even more suitable for 
vaccination purposes (187).
immune Stimulating Complexes
Immune stimulating complexes (ISCOMs) are negatively charged 
self-assembling pentagonal dodecahedrons cage-like rigid struc-
tures with a size of 30–40 nm. They can form spontaneously after 
mixing Ags with cholesterol, phospholipids (usually phosphati-
dylethanolamine and phosphatidylcholine), and the saponin 
Quil A extracted from the bark of Quillaja saponaria Molina tree. 
Interestingly, such formulation allows to reduce the toxicity asso-
ciated with saponin administration, while retaining its adjuvant 
activity (188, 189). Proteins or glycoproteins that are normally 
anchored by a hydrophobic transmembrane sequence into the 
cell membrane can be incorporated as such. Non-amphipatic pro-
teins or peptides have to be modified by attachment of a lipid tail 
(e.g., palmitic acid). Immunization with ISCOMs induced both 
Th1-type humoral and cellular responses, including cytotoxic 
T  lymphocytes that are important to fight against intracellular 
pathogens (190). Several studies have reported potent induction 
of mucosal immune responses, including robust IgA production 
in nasal washes and the lung, after nasal/pulmonary vaccination 
with ISCOMs harboring antigenic entities from Influenza virus 
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(191–194), respiratory syncitial virus (195), Hepatitis B virus 
(196) and measles (197). Protective efficacy was observed as well 
after vaccination with an Influenza subunit vaccine composed of 
ISCOMs (198), adjuvanted ISCOM-based anti-M. tuberculosis 
and anti-Influenza vaccines (199, 200) and Helicobacter pylori-
Ags delivered via ISCOMs (201). In some cases, such immuniza-
tion proved more efficient than parenteral injection (196, 202). 
Production of ISCOMs with an alternative saponin, derived from 
Quilaja brasiliensis, also allowed to induce mucosal local and 
distant IgA production after nasal delivery of an OVA-based vac-
cine (203). In addition, incorporation of DNA plasmid within the 
ISCOM matrix elicited potent anti-Haemophilus influenzae cel-
lular and Ab responses in the nasopharynx of nasally immunized 
animals (204). Oral administration of ISCOM-based vaccines has 
been evaluated (205, 206); however, it seems that the generation of 
intestinal IgA responses was limited (207). Although ISCOMs are 
self-adjuvanted delivery systems, incorporation of the adjuvant 
CTA1-DD within the structure allowed to induce robust mucosal 
IgA production and T cell proliferation, together with systemic 
responses, after nasal administration (208). Such an approach has 
also been evaluated via oral delivery. Potent systemic Th1-type 
immune responses were induced, but unfortunately the mucosal 
compartments were not analyzed (209). CTA1-DD/ISCOMs 
incorporating major outer membrane protein from Chlamydia 
muridarum have also been administered via the vaginal route. 
Vaccination induced limited Ab responses, but clearly detectable 
CD4 T  cell responses in vaginal tissues. This led to protection 
against a bacterial challenge, as demonstrated by reduction in 
bacterial shedding from the genital tract (49). Overall, the use 
of ISCOMs as a delivery vehicle for mucosal vaccination finds its 
best applicable for nasal administration, even though the sublin-
gual route remains to be explored. Nevertheless, the difficulties 
related to the use of hydrophilic Ags that have to be modified 
before incorporation within ISCOMs, together with the reported 
toxicity of saponin, somehow limits the wide use of such vaccina-
tion approach.
Others
Oil-in-water nanoemulsions disperse into nanosized droplets 
and exhibit long-term colloidal stability. They can encapsulate 
hydrophilic or hydrophobic payload, respectively, and have been 
tested for nasal vaccination. A nanoemulsion based on soybean 
oil and cetylpiridinium chloride (W805EC) has been shown to 
deliver its antigenic payload across ciliated nasal epithelial cells 
and to the regional LNs in the NALT through migrating activated 
DCs (210). Via TLR-2 and TLR-4, such vaccine formulation 
promoted the induction of robust Ab and Th1-/Th17-type cel-
lular responses and when associated with inactivated Influenza 
vaccine, generated a protective immunity against Influenza chal-
lenge (211). Such an approach similarly proved efficient in animal 
models to fight against M. tuberculosis, Hepatitis B, and Bacillus 
anthracis infections, or to generate HIV-1-specific mucosal 
immune responses (212, 213). Improved stability of nanoemul-
sions for mucosal delivery can now be achieved by the double 
emulsion water-in-oil-in-water technology, which has been 
applied both nasally and orally and resulted in robust production 
of systemic IgG and mucosal IgA (214). Alternatively, coupling 
of lipopeptides with a polylysine core induces the formation of 
5–15 nm particles that can promote the generation of systemic 
and mucosal IgG/IgA and T cell responses after nasal administra-
tion. In these conditions, protective responses have been obtained 
against S. pyogenes infection (215, 216).
HUMAN APPLiCATiON OF LiPiD 
PARTiCLeS FOR MUCOSAL vACCiNATiON
Currently approved mucosal vaccines are composed of live-
attenuated or killed whole-pathogen cells that offer relatively 
good efficacy, but cannot be administered to young infants, 
immunocompromised people and the elderly due to potential 
safety issues. The majority of mucosally administered vaccines 
in humans are delivered via the oral route and directed against 
enteric infections such as polio, cholera, typhoid fever, and rotavi-
rus infection (14). Oral polio vaccine has been used for more than 
50 years with great success and is a prototypical vaccine for polio 
eradication in many countries. Interestingly, it demonstrated 
improved efficacy as compared to an inactivated pathogen vaccine 
injected parenterally (217–219). Vivotif®, as well as Dukoral®, 
Shanchol™, Orochol®/Vaxchora™, and mORC-Vax™, are 
live-attenuated or whole-killed vaccines against Salmonella-
induced typhoid fever or Vibrio cholerae infections, respectively 
(220–222). As expected based on preclinical studies in animal 
models, their protective efficacy has been correlated with effector 
immune responses present at mucosal surfaces (in most cases 
detection of SIgA in mucosal fluids) and induction of plasma cells 
expressing gut-homing molecules specific for the small intestine 
and the colon (223–225). In addition, and similar to observations 
in animal models, the choice of the administration route impacts 
on the tropism of the induced mucosal immune responses 
(226). Only FluMist®, a live-attenuated Influenza virus vaccine, 
is licensed for nasal administration (227). It demonstrates high 
level of protection against matched and mismatched viral strains 
in children and adults and proved more efficient than parenteral 
vaccination (228). Virus-specific mucosal IgA and systemic IgG 
responses with a possible role for cell-mediated immunity has 
been documented in vaccinated individuals (229). So far, the 
only adjuvant used for vaccinal application to mucosae is the B 
subunit of CT, which has been included in Dukoral® to improve 
the immunogenicity of the killed whole-pathogen Vibrio cholerae 
vaccine.
Despite many encouraging results obtained in proof-of-con-
cept and preclinical animal models, a limited number of subunit 
vaccines based on lipidic delivery systems has been evaluated 
and/or approved for human use, especially for mucosal admin-
istration (Table 2) (230). Interestingly, in the context of mucosal 
vaccination, at least three formulations have been evaluated in 
early phase clinical trials. Nasal administration of the oil-in-water 
nanoemulsion W805EC combined with the approved inactivated 
systemic Influenza vaccine Fluzone® has demonstrated induction 
of IgA responses in nasal washes in a clinical evaluation (231). 
In addition, virosome-based and ISCOM-based Influenza vac-
cines are currently under development for administration via the 
nasal route (232, 233). Systemic injection of virosomes has been 
TABLe 2 | Examples of licensed and in development lipid-based vaccines for human use.
Admin. 
routes




Phase 3 trial of AS01 against malaria (239)
Phase 3 trial of AS01 against varicella-zooster virus (240)
Phase 1 trial of CAF01 against tuberculosis (230)
Safe and well tolerated
Safe and well tolerated
Unknown to date
Adjuvanted with saponin and 
monophosphoryl lipid A
Evaluated in the elderly




Licensed vaccines against Influenza and Hepatitis (234)
Clinical evaluation against Influenza (232)
Safe and well tolerated
Unknown to date









Phase 1 trial against HCV (243)
Phase 1 trial against HPV (241, 242)
Clinical evaluations against Influenza (189)





Tested in healthy adults and elderly





Licensed vaccines against Influenza containing MF59 (236)
Licensed vaccines against Influenza containing AS03 (237)
Phase 1 clinical trial of W805EC (231)
Some levels of reactogenicity 
depending on formulations
Well-tolerated, no significant 
adverse events
Additional formulations in clinical 
evaluation
I.m., intramuscular; I.n., intranasal; I.v., intravenous.
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licensed for human vaccination against hepatitis A (Epaxal®) and 
Influenza (Inflexal V®) (234). Additional vaccines based on such 
technology have been tested in Phase 1 clinical trial for malaria 
and Influenza via the systemic route (232, 235). The advantage of 
such approach is that virosomes are self-adjuvanted, which is not 
the case for all other lipid-based delivery systems. Two Influenza 
vaccine formulations composed of squalene-based nanoemul-
sions (MF59® and AS03) are also approved for intramuscular 
injection in humans, with a particular focus on use in young 
children and elderly (236, 237). At least three additional strategies 
have been evaluated in humans. The most promising one is the 
use of the AS01 adjuvant, composed of liposomes made of highly 
unsaturated neutral phospholipids including MPLA and saponin 
QS21 (238). Successful phase III vaccination trials of such deliv-
ery system have been performed with the RTS,S/Mosquirix™ 
vaccine formulation against malaria (239) and the herpes-zooster 
vaccine (HZ/su) (240). CAF01 is an alternative formulation that 
is currently tested for parenteral vaccination against tubercu-
losis. Such liposomal bilayer preparation contains the cationic 
lipid DDA and the glycolipid TDB as immunostimulator (152). 
ISCOMs incorporating Ags E6 and E7 from HPV16 have been 
tested in women with cervical intraepithelial neoplasia and HIV-
positive individuals with oncogenic HPV infections (241, 242). 
They demonstrated a safety profile and induced specific humoral 
and effector T cell responses. Similar results were obtained fol-
lowing vaccination with HCV-derived antigenic entities (243). 
Additional vaccine preparations based on lipidic constructs are 
currently evaluated to fight against pathogen infections, such as 
malaria, dengue fever, HIV, or Influenza (90, 230).
Nevertheless, the above-mentioned studies are mainly per-
formed with systemically injected formulations and only rare 
mucosal applications have been assessed. The use of mucosal 
route of administration requires that anatomical, functional, and 
immunological characteristics are taken into consideration and 
differences between humans and animals may results in poor 
inter-species translation of promising results (13). An organized 
NALT similar to that present in mice is not found in humans. 
By contrast, alternative inductive sites in the form of immune 
nodules are present in humans in the upper nasal cavity, in 
the concha, and in Waldeyer’s rings (adenoids, tonsils) (244). 
Pulmonary delivery of vaccines does not seem to be optimal as 
well, because BALT have only been reported in fetuses and young 
children, but not in healthy adults. In addition, the localization 
and phenotype of DCs in the nasal cavity and in the lung all differ 
between mice and humans. Taking into account these considera-
tions, sublingual administration sounds like a promising strategy 
(42). Indeed, immunological and physiological organization of 
the oral cavity is similar in both mice and humans, with docu-
mented presence of the same DC subsets, such as Langerhans 
cells, capable of eliciting immunogenic or tolerogenic responses 
depending on the applied formulations. Vaccination via the sub-
lingual route has been mostly evaluated in humans for allergen 
immunotherapy, and has been shown to induce systemic IgG 
(focus of allergy) (245). Therefore, evaluation of the mucosal 
vaccination approach to protect against infectious diseases is 
highly relevant and needs evaluation. In addition, although the 
gut immune system is relatively similar between both species, 
oral administration of subunit vaccines is further complicated 
due to the constraints related to the stability of formulations in 
the aggressive environment of the digestive tract. On the top of 
anatomical considerations, the age-related decline in the immune 
function, possibly related to the documented decrease in M cell 
differentiation with age, represents a drawback for immunization 
in eldery people.
CONCLUSiON AND PeRSPeCTiveS
Although vaccination has led to the control of several diseases and 
has demonstrated substantial technological progresses, humans 
still suffer from infections leading to death and increasing health 
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costs. Many infectious diseases for which the development of 
effective vaccines is urgently needed include those transmitted 
through various mucosal routes that affect the gastrointestinal 
tract (E. coli, Salmonella, Shigella, Vibrio cholerae, H. pylori), the 
respiratory tract (Influenza, M. tuberculosis, respiratory syncitial 
virus) or are sexually transmitted (HIV, Chlamydia) (15). To 
date, parenteral vaccination represents an important part of the 
administered vaccines, despite the fact that they poorly induce 
mucosal immune responses. Furthermore, the requirement for 
sterile needles, their subsequent elimination, the associated cost, 
and the cold chain’s requirement in many instances prompt a 
shift toward reduced frequencies of intramuscular vaccination. 
In addition, most of the currently licensed vaccines can only 
be administered over 2  years of age for safety reasons; similar 
considerations apply for immunodeficient individuals and elderly 
(13). Therefore, the mucosal application of subunit vaccines rep-
resents a sound alternative to broaden the target population that 
could benefit from vaccination. Cues into this direction include 
recent advances in the understanding of mucosal immunity 
as well as assessment of correlates of protection may help to 
develop promising mucosal vaccines; in this respect, design of 
novel effective delivery strategies will permit to achieve mucosal 
vaccines that induce protective neutralizing SIgA, together with 
CTLs and effector CD4 T cells mainly secreting IFN-γ and IL-17. 
Moreover, because they are considered as safe, subunit vaccines 
can certainly be administered to neonates and young infants who 
already possess a functional mucosal immune system (13).
Lipid-based particles fulfill the requirements for better 
efficiency, safety, low-dose Ag, and ease to handle logistically. 
They can deliver a wide range of antigenic entities upon mucosal 
delivery and can be tailored to obtain vaccine formulations 
with appropriate properties to address questions related to the 
mechanisms invlolved in the control of the pathogen and the 
route of administration. Robust and sustained induction of 
immune responses, comprising production of SIgA at mucosal 
surfaces, together with helper and cytotoxic T  cells, often cor-
relate with protection in defined animal models under study; 
this will undoubtly help to drive vaccine development toward the 
right direction. It remains that a strict comparative analysis of 
the formulations and administration routes to be used against a 
particular infectious disease is rarely performed within the same 
study. To contribute to the identification of such a missing piece 
in this complex puzzle would be an asset in order to optimize 
mucosal vaccination. The same lack of information must be filled 
up when one deals with the definition of the optimal dosing and 
schedule of administration to ensure efficient priming and boost-
ing of immune responses aiming at reaching optimal magnitude 
and maintenance.
Some lipid-based preparations have the advantage of being 
lyophilized, thus allowing to simplify the logistics usually neces-
sary for cold chain. Indeed, some of these formulations can be 
stored at room temperature for several months and can be admin-
istered in such form via the nasal, oral, or sublingual routes. Dry 
powder nasal vaccines have already been tested (246), oral deliv-
ery of capsules is not a problem (222), and many allergy-related 
immunotherapy tablets have been considered for sublingual 
administration (247). Moreover, lipid-based preparations can be 
aerosolized, which might represent an alternative procedure to 
keeping stable vaccine preparations. Overall, great expectations 
are coming from the lipid-based vaccine formulations currently 
evaluated in clinical trials in humans, which together with the 
different mechanisms of mucosal immunity recently unraveled, 
may likely favor the development of future mucosal vaccines 
suitable for a majority of individuals, thanks to the combinatorial 
flexibility offered by the nature of the constituents available.
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